Back to top

Analyst Blog

RedHill Biopharma Ltd. (RDHL) currently does not have any approved product in its portfolio and is making efforts to invest in the development of its late-stage candidates.

RedHill Biopharma recently announced that it has entered into a definitive agreement with Broadfin Capital LLC. The agreement relates to the sale of  RedHill Biopharma’s American Depository Shares (ADSs) and warrants in a private placement transaction for $2.5 million (1 ADS = 10 ordinary shares).

RedHill Biopharma expects to use the proceeds from the sale for general working capital and development of its leading gastrointestinal candidates, RHB-104 for Crohn's disease and RHB-105 for Helicobacter pylori infection.

The private placement is expected to close by Jan 11, 2014. As per the agreement, upon closing, RedHill Biopharma will issue Broadfin Capital a total of 263,160 units. Each unit will consist of one ADS and a warrant to purchase 0.4 of an ADS, at a cost of $9.50 per Unit.

RedHill Biopharma will issue Broadfin Capital warrants to purchase 105,264 ADSs in total, which will have a three-year term and exercisable at a price of $11 per ADS.

A day before this transaction, RedHill Biopharma entered into an agreement with OrbiMed Israel Partners Limited Partnership for the sale of RedHill Biopharma’s ADSs and warrants in a private placement transaction for $6 million.

RedHill Biopharma currently carries a Zacks Rank #2 (Buy). Investors may consider companies like Jazz Pharmaceuticals (JAZZ - Analyst Report), Lannett Co., Inc. (LCI - Snapshot Report) and WuXi PharmaTech (Cayman) Inc. (WX - Snapshot Report). All three carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.